 Zacks Investment Research downgraded shares of Champions Oncology NASDAQ:CSBR from a buy rating to a hold rating in a report released on Friday morning, Zacks.com reports. According to Zacks, Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. ... 